The monoaza analogues of sulfones � sulfoximines � are an underrepresented pharmacophore in drug discovery approaches, even though they offer very interesting properties to the medicinal chemist.  In the discovery process of the pan-CDK inhibitor BAY 1000394 (roniciclib), for example, the unconventional proposal to introduce a sulfoximine group into the lead series initially led to raised eyebrows, since sulfoximines have seldom been used in drug discovery. However, it was the introduction of the sulfoximine group that finally allowed the fundamental issues of the project to be overcome, culminating in the identification of the clinical sulfoximine pan-CDK inhibitor BAY 1000394. Based on the case study of BAY 1000394, this presentation provides an overview on the properties of the sulfoximine group and its rather limited history in medicinal chemistry approaches, focusing on selected examples where the concept for its use as a pharmacophore and the outcome are available.

Sulfoximines: A neglected opportunity in medicinal chemistry

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.